Get a glimpse into our company and investor data—powered by the PitchBook Platform
Series ALATEST DEAL TYPE
$1MLATEST DEAL AMOUNT
Developer of novel small molecule therapeutics capable of preventing tumors from evading the immune system. The company focuses on immuno-oncology pathways and mechanisms that can be best targeted by small molecule therapeutics.